{"id":3194,"date":"2018-09-18T12:28:08","date_gmt":"2018-09-18T06:58:08","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=3194"},"modified":"2021-07-24T12:57:03","modified_gmt":"2021-07-24T07:27:03","slug":"notizia-73","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-73","title":{"rendered":"Notizia"},"content":{"rendered":"<p><strong>Argenx gets green cue in phase 2 in primary immune thrombocytopenia<\/strong><\/p>\n<p>The Belgian biotech, <strong>Argenx<\/strong> has\u00a0cleared\u00a0<strong>phase 2<\/strong> data on <strong>efgartigimod<\/strong> in <strong>primary immune <a href=\"https:\/\/www.delveinsight.com\/report-store\/thrombocytopenia-market-2027\">thrombocytopenia<\/a> (ITP)<\/strong>. The results that they received, indicate at the effectiveness of the antibody <strong>Fc fragment<\/strong> in patients with the <strong>autoimmune bleeding disorder<\/strong>. ITP patients suffer from low platelet counts. If platelet levels plunge, then bleeding inside the brain can cause serious complications. Doctors manage the disease by using either <strong>corticosteroids<\/strong> or <strong>SYK inhibitor Tavalisse <\/strong>of<strong> Rigel Pharmaceuticals<\/strong>, but Argenx ruminates of safer and more broadly effective therapy. To this, Chief Medical Officer of\u00a0Argenx apprise of Efgartigimod being the potential to address ITP in a unique way across patient types, targeting disease at the source by removing IgGs and restoring platelet numbers.<\/p>\n<p><strong>FDA uplifts clinical hold from breast cancer trial of <\/strong><strong>Mersana Therapeutics<\/strong><\/p>\n<p>The <strong>FDA<\/strong> has lifted the partial clinical hold from <strong>phase 1<\/strong> of <strong>HER2-targeted antibody-drug conjugate (ADC)<\/strong> of <strong>Mersana Therapeutics<\/strong>. It was on hold due to death of a participant in the <strong>XMT-1522 <\/strong>breast cancer trial. Mersana has come out from the partial hold by approving to increase monitoring and eliminate patients with advanced hepatic impairment from the trial.<\/p>\n<p><strong>FDA takes time to review levodopa inhaler of Acorda for Parkinson\u2019s disease<\/strong><\/p>\n<p><strong>FDA<\/strong> has extended the review of <strong>Acorda Therapeutics<\/strong>\u2019 drug-device combination treatment for <strong>Parkinson\u2019s disease<\/strong>. As, FDA asked for additional information on chemistry, manufacturing and controls, so, the chief amendment to its application will take more time to review.<\/p>\n<p><strong>FDA clears first rescue stent to seal coronary artery tears <\/strong><\/p>\n<p>The <strong>FDA<\/strong> permitted a new emergency <strong>stent device<\/strong> to treat perforations in the <strong>blood vessels<\/strong> of the <strong>heart<\/strong>. Deep tears in <strong>coronary arteries<\/strong> can arise in rare instances during percutaneous interventions, where stents are inserted through a catheter to enlarge narrowed vessels to increase blood flow to the heart.<\/p>\n<p><strong>\u00a0<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Argenx gets green cue in phase 2 in primary immune thrombocytopenia The Belgian biotech, Argenx has\u00a0cleared\u00a0phase 2 data on efgartigimod in primary immune thrombocytopenia (ITP). The results that they received, indicate at the effectiveness of the antibody Fc fragment in patients with the autoimmune bleeding disorder. ITP patients suffer from low platelet counts. If platelet [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2465,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1827,1817,1815,1830,1832,1578,1816,1819,704,1831,1822,1828,1824,1826,1823,1818,1820,1829,1821,1825],"industry":[17225],"therapeutic_areas":[17242,17233,17245,17228],"class_list":["post-3194","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-acorda","tag-argenx","tag-autoimmune-bleeding-disorder","tag-blood-vessels","tag-coronary-arteries","tag-corticosteroids","tag-efgartigimod","tag-fc-fragment","tag-fda","tag-heart","tag-her2-targeted-antibody-drug-conjugate-adc","tag-levodopa-inhaler","tag-mersana-therapeutics","tag-parkinsons-disease","tag-phase-1","tag-phase-2","tag-rigel-pharmaceuticals","tag-stent-device","tag-syk-inhibitor-tavalisse","tag-xmt-1522","industry-pharmaceutical","therapeutic_areas-cardiovascular-diseases","therapeutic_areas-hematological-disorders","therapeutic_areas-neurology","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Notizia |18\/09\/2018 - DelveInsight Business Research LLP<\/title>\n<meta name=\"description\" content=\"The FDA has lifted the partial clinical hold from phase 1 of HER2-targeted antibody-drug conjugate (ADC) of Mersana Therapeutics.....\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-73\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Notizia |18\/09\/2018 - DelveInsight Business Research LLP\" \/>\n<meta property=\"og:description\" content=\"The FDA has lifted the partial clinical hold from phase 1 of HER2-targeted antibody-drug conjugate (ADC) of Mersana Therapeutics.....\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-73\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-09-18T06:58:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1112\" \/>\n\t<meta property=\"og:image:height\" content=\"660\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Notizia |18\/09\/2018 - DelveInsight Business Research LLP","description":"The FDA has lifted the partial clinical hold from phase 1 of HER2-targeted antibody-drug conjugate (ADC) of Mersana Therapeutics.....","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-73","og_locale":"en_US","og_type":"article","og_title":"Notizia |18\/09\/2018 - DelveInsight Business Research LLP","og_description":"The FDA has lifted the partial clinical hold from phase 1 of HER2-targeted antibody-drug conjugate (ADC) of Mersana Therapeutics.....","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-73","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-09-18T06:58:08+00:00","article_modified_time":"2021-07-24T07:27:03+00:00","og_image":[{"width":1112,"height":660,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-73","url":"https:\/\/www.delveinsight.com\/blog\/notizia-73","name":"Notizia |18\/09\/2018 - DelveInsight Business Research LLP","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-73#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-73#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","datePublished":"2018-09-18T06:58:08+00:00","dateModified":"2021-07-24T07:27:03+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The FDA has lifted the partial clinical hold from phase 1 of HER2-targeted antibody-drug conjugate (ADC) of Mersana Therapeutics.....","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-73"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-73#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","width":1112,"height":660,"caption":"transthyretin amyloidosis"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia-300x178.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Acorda<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Argenx<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">autoimmune bleeding disorder<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">blood vessels<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">coronary arteries<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">corticosteroids<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">efgartigimod<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Fc fragment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">heart<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">HER2-targeted antibody-drug conjugate (ADC)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">levodopa inhaler<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Mersana Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Parkinson\u2019s disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">phase 1<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">phase 2<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Rigel Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">stent device<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">SYK inhibitor Tavalisse<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">XMT-1522<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Acorda<\/span>","<span class=\"advgb-post-tax-term\">Argenx<\/span>","<span class=\"advgb-post-tax-term\">autoimmune bleeding disorder<\/span>","<span class=\"advgb-post-tax-term\">blood vessels<\/span>","<span class=\"advgb-post-tax-term\">coronary arteries<\/span>","<span class=\"advgb-post-tax-term\">corticosteroids<\/span>","<span class=\"advgb-post-tax-term\">efgartigimod<\/span>","<span class=\"advgb-post-tax-term\">Fc fragment<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">heart<\/span>","<span class=\"advgb-post-tax-term\">HER2-targeted antibody-drug conjugate (ADC)<\/span>","<span class=\"advgb-post-tax-term\">levodopa inhaler<\/span>","<span class=\"advgb-post-tax-term\">Mersana Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Parkinson\u2019s disease<\/span>","<span class=\"advgb-post-tax-term\">phase 1<\/span>","<span class=\"advgb-post-tax-term\">phase 2<\/span>","<span class=\"advgb-post-tax-term\">Rigel Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">stent device<\/span>","<span class=\"advgb-post-tax-term\">SYK inhibitor Tavalisse<\/span>","<span class=\"advgb-post-tax-term\">XMT-1522<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Sep 18, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Sep 18, 2018 12:28 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"transthyretin amyloidosis","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3194","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=3194"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3194\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2465"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=3194"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=3194"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=3194"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=3194"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=3194"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}